In relation to rheumatoid arthritis (RA), Yang et al.'s study suggests that MYC and FOXO1 genes are implicated (Yang et al., 2020b), making these genes suitable candidates for targeted treatment using CRISPR/Cas9. The gene discussed is MYC; the disease is rheumatoid arthritis.